Although PD-L1 immunohistochemistry has been approved by the Food and Drug Administration as the only predictive companion diagnostic test to determine whether pembrolizumab should be used for non-small cell lung cancer patients, improved survival outcomes have been seen in many PD-L1-negative patients [48]. Here, CD274 is linked to non-small cell lung carcinoma.